Brentuximab vedotin for CD30-positive tumours.
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. Electronic address: shigmasuda@gmail.com.
Shigeo
S
Masuda
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Shigeru
S
Miyagawa
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Terumi
T
Nakamura
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Maaz Asher
MA
Khurram
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Yoshiki
Y
Sawa
D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology*; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
D000074322:Antineoplastic Agents, Immunological; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin